Product Program year 2020 Source: CMS Open Payments

Lonhala Magnair

Drug Respiratory

NDC 63402-201-00

Open in the dashboard

General payments

$2,269,055

53,820 payments

Research payments

$0

0 payments

Through program year 2020, $2,269,055 in general payments and $0 in research payments were reported against Lonhala Magnair (Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2020 General $200,139 8,871
2019 General $2,068,916 44,949

Breakdown

Who paid General payments · program years 2019–2020
  1. Sunovion Pharmaceuticals Inc. $2,269,055 53,820 payments
Top recipients General payments · program year 2020
  1. David Pham Pulmonary Disease · Westminster, CA $17,939 9% · 26 payments
  2. Sandra Schuldheisz Somerset, KY $11,069 6% · 52 payments
  3. Antonio Anzueto Pulmonary Disease · San Antonio, TX $10,805 5% · 9 payments
  4. Jeffrey Cary Pulmonary Disease · Seattle, WA $5,335 3% · 5 payments
  5. Donald Mahler Pulmonary Disease · Lebanon, NH $4,050 2% · 3 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Pulmonary Disease Internal Medicine $96,872 51% · 1,129 practitioners
  2. Internal Medicine $37,498 20% · 874 practitioners
  3. Family Medicine $31,915 17% · 980 practitioners
  4. Critical Care Medicine Internal Medicine $5,479 3% · 132 practitioners
  5. Allergy & Immunology $2,953 2% · 59 practitioners

The top 5 of 58 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. California $28,633 14% · 260 recipients
  2. Texas $24,463 12% · 290 recipients
  3. Florida $17,544 9% · 246 recipients
  4. Kentucky $14,318 7% · 71 recipients
  5. Georgia $8,653 4% · 144 recipients

The top 5 of 46 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

53,820 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record